# Esperion Therapeutics

> Public biotech developing oral non-statin LDL-cholesterol therapies (NEXLETOL/NEXLIZET).

## Why it is interesting

Ann Arbor public biotech (NASDAQ:ESPR) — university-adjacent cardio-metabolic commercialization.

## Profile

- **Latest funding:** Not publicly disclosed
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** public
- **Status:** public
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** stub
- **Last updated:** 2026-07-26

## Key facts

- NASDAQ:ESPR
- HQ Ann Arbor, MI
- NEXLETOL / NEXLIZET franchise

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** July 26, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/esperion-therapeutics